⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Post-market surveillanceNeuropeptide

Compound 61407

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061407
Risk Class
MODERATE
Last Audit
Jan 24, 2108

Research Abstract

Neuropeptide candidate engineered for endocrine support initiatives with automated dossier coverage.

Compound 61407 is a neuropeptide asset inside neuropeptide innovation track initiatives, optimized for endocrine support and performance longevity.

The dossier currently sits in post-market surveillance with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061407 with updates logged 2108-01-24.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Endocrine supportPerformance longevity

Nomenclature

CX-61407Neuropeptide Program 61407

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061407
  2. [2] Operations Pulse • Neuropeptide innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61407